Zampilimab, designated as UCB-7858 or 2098280-42-1, represents a innovative therapeutic agent targeting TGM2, a molecule involved in fatty acid metabolism and possibly implicated in various immunological disorders. This modified immunoglobulin demonstrates marked effectiveness in early research , indicating a function in modulating the process u… Read More

Glembatumumab vedotin represents a innovative method in cancer management. This ADC specifically binds to an receptor present on several cancer cells, delivering an powerful cytotoxic agent. Initial patient trials indicate substantial effect against certain hematological cancers and are now being assessed for their potential in treating solid ca… Read More